Pregnancy, drinking too much water before bed or certain conditions that tend to be more common as you age can make middle-of ...

The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.

Boris had his bikes and a wave. Truss had her shambolic-onomics. Andy Burnham hasn’t entered Downing Street yet, but he’s already got an eponym: the “Burnham belly”.

A new study from the University of Florida College of Medicine and the Johns Hopkins Bloomberg School of Public Health found that untreated sleep apnea is associated with a 69% faster decline in ...

Swindon's Great Western Hospital is one of five trust offering a new treatment for sleep apnoea.

Resmed remains the best performer of biotech's Big Four, but some investors aren't sleeping tight after last week's $700 ...

Cambridge biotech Apnimed has filed for an initial public offering as it awaits Food and Drug Administration approval for its ...

Apnimed is having sweet dreams of an IPO that could fund the planned commercial launch of an obstructive sleep apnea (OSA) therapy that is currently awaiting an FDA approval decision. The therapy, ...

Some companies are shifting towards influencer-style videos – but with regular customers and employees, not cultivated internet personalities.

Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering ​in the U.S. on Friday.

Apnimed Inc. filed for a US initial public offering, as its oral drug to treat obstructive sleep apnea moves closer to being commercialized.

A team of researchers from the University of Auckland is studying a promising new medicine that may one day help people living with both heart failure and sleep apnea. Although the treatment is still ...